We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

84 hedge funds and large institutions have $184M invested in Kalaris Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 26

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0.12% more ownership

Funds ownership: 1.7% → 1.81% (+0.12%)

0% more funds holding

Funds holding: 84 → 84 (0)

44% less capital invested

Capital invested by funds: $329M → $184M (-$145M)

Holders
84
Holders Change
–
Holders Change %
0%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
28
Reduced
26
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$12.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.82M
3
GC
GMT Capital
Georgia
+$4.04M
4
JP Morgan Chase
JP Morgan Chase
New York
+$1.44M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$1.1M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$5.62M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$3.38M
3
EOJOAM
E. Ohman J:or Asset Management
Sweden
-$1.18M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1,000K
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$816K
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$151K – – –
Barclays
52
Barclays
United Kingdom
$131K +$168K +844 New
SFI
53
Susquehanna Fundamental Investments
Pennsylvania
$127K -$35.1K -176 -18%
MIM
54
MetLife Investment Management
New Jersey
$122K +$53.3K +267 +52%
Invesco
55
Invesco
Georgia
$99K +$997 +5 +0.8%
HF
56
HRT Financial
New York
$93K +$120K +602 New
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$90.7K -$23.1K -116 -17%
Handelsbanken Fonder
58
Handelsbanken Fonder
Sweden
$90K – – –
New York State Common Retirement Fund
59
New York State Common Retirement Fund
New York
$89K -$70.2K -352 -38%
Legal & General Group
60
Legal & General Group
United Kingdom
$85K +$1.2K +6 +1%
ProShare Advisors
61
ProShare Advisors
Maryland
$84K -$28.9K -145 -21%
VOYA Investment Management
62
VOYA Investment Management
Georgia
$77K – – –
VEA
63
Virtus ETF Advisers
New York
$71K -$5.39K -27 -6%
Jane Street
64
Jane Street
New York
$69K +$89K +446 New
Citigroup
65
Citigroup
New York
$41K -$446K -2,234 -90%
Ensign Peak Advisors
66
Ensign Peak Advisors
Utah
$39K – – –
TRCT
67
Tower Research Capital (TRC)
New York
$37K +$20.7K +104 +78%
AB
68
Amalgamated Bank
New York
$33K +$41.7K +209 New
AF
69
Amalgamated Financial
New York
$33K +$41.7K +209 New
AIP
70
Ameritas Investment Partners
Nebraska
$16K – – –
PHK
71
Point72 Hong Kong
Hong Kong
$16K +$7.98K +40 +63%
PFS
72
Prospera Financial Services
Texas
$16K +$20.5K +103 New
QT
73
Quantbot Technologies
New York
$15K -$1.79K -9 -8%
Royal Bank of Canada
74
Royal Bank of Canada
Ontario, Canada
$14K -$38.5K -193 -68%
Canada Life
75
Canada Life
Manitoba, Canada
$14K – – –
1 2
3
4

KLRS Hedge Fund Activity: Q1 2022 in Review

84 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2022, worth a combined $184M — down 44% from $329M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KLRS positions and 14 closed out — a net gain of 1 holder — while 28 added to existing stakes and 26 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $12.5M. The largest seller was State Street, cutting an estimated $5.62M.

  • 84 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $184M of Kalaris Therapeutics stock for Q1 2022, down 44% quarter-over-quarter.
  • 15 funds opened new Kalaris Therapeutics positions in Q1 2022 and 14 closed out, a net change of +1 holder.
  • The largest Kalaris Therapeutics buyer in Q1 2022 was RA Capital Management, an estimated $12.5M added.
  • The largest Kalaris Therapeutics seller in Q1 2022 was State Street, an estimated $5.62M sold.

Based on aggregated 13F filings for Q1 2022.